Corporate Magazine 2012 - Boehringer Ingelheim

ingredients for clinical trials, and is scheduled for completionat the start of 2014.Human PharmaceuticalsResearch and development activities, with our large researchsites in Germany (Biberach), the USA (Ridgefield)and Austria (Vienna), were focused on the following indicationareas:• Respiratory diseases• Cardiometabolic disorders(cardiovascular and metabolic diseases)• Oncology• Diseases of the central nervous system• Immunology• Infectious diseasesThe 2012 financial year saw the launch of the “DiseaseMap 2025”, which is aimed at constantly reviewing thefocus of the Prescription Medicines division with regardto indication areas and diseases to be treated. In a fastchangingexternal environment, it stipulates targets andcore areas in research, development and medicine wherewe want to develop our division. In the context of thisextensive review, Boehringer Ingelheim decided to stopits research work on virology. This led to the closure of theresearch site in Laval, Canada, which will be shut downin the first quarter of 2013. The reason for this is a trendtowards treating infectious diseases with vaccinations,an area in which Boehringer Ingelheim is not active.Boehringer Ingelheim is one of the world’s leading pharmaceuticalcompanies in the treatment of respiratorydiseases. So far, the most successful product from inhouseresearch is tiotropium, which has been availablefor ten years under the product name spiriva® and isused to treat chronic obstructive pulmonary diseases(COPD). The company currently has an extensive researchand development pipeline for treatment of COPD, asthma,idiopathic pulmonary fibrosis and lung cancer.Overall, various preparations in early phases of clinicaldevelopment (phase I and II) and additional active ingredientsin late development phases (phase III and approval)are available. One example is the respiratoryproduct olodaterol, a long-acting beta-2 agonist for treatingCOPD. Olodaterol is in the approval process and wasprimarily developed as a combination product for tiotropiumin the long-term treatment of COPD. The test substancenintedanib is a tyrosine kinase inhibitor for treatingidiopathic pulmonary fibrosis (IPF), and has shownpromising results in a clinical phase II study. IPF is arare disease with a high mortality rate a few years afterdiagnosis, meaning that there is a significant medicalneed for effective new treatments. Regarding this substance,admission of patients for the approval-relatedphase III study INPULSIS was completed in the secondquarter of 2012. The outcome of this study is expectedin 2014. The results of the phase III study PrimoTinA-Asthma showed that asthma patients who retainedsymptoms despite currently known treatment options reducedtheir exacerbations when treated with tiotropiumResearch and development 2012 2011 2010 2009 2008Expenditure in millions of EUR 2,795 2,516 2,453 2,215 2,109– as % of net sales 19.0 19.1 19.5 17.4 18.2Prescription Medicines expenditure in millions of EUR 2,563 2,372 2,306 2,100 2,016– as % of Prescription Medicines net sales 22.5 23.5 23.8 20.9 22.1Average number of employees 7,492 7,159 7,093 6,934 6,788Investments in tangible assets (without investments in infrastructure) in millions of EUR 139 112 83 125 14524Boehringer Ingelheim annual report 2012